psychedelics | CARLAT PUBLISHING

MDMA: What Went Wrong Part 2

June 17, 2024

Chris Aiken, MD and Kellie Newsome, PMHNP

Did boundary violations sink MDMA-assisted therapy, or was there something more? In part II of our series, we look at what else went wrong.

MDMA: What Went Wrong Part 1

June 10, 2024

Chris Aiken, MD

Did boundary violations sink MDMA assisted psychotherapy? We explore the reasons behind the FDA panel’s rejection of this psychedelic therapy.

Expert Q&A

Ketamine Use and Misuse

April 1, 2024

Keith A. Trujillo, PhD

Keith A. Trujillo, PhD.

Emeritus Professor of Psychology, California State University, San Marcos, CA.

Dr. Trujillo has no financial relationships with companies related to this material.

Ketamine and esketamine represent some of the most powerful rapid-acting agents in our armamentarium of treatments for depression. However, ketamine is also an addictive substance, and there is emerging evidence that the widespread use of ketamine may be causing more patient harms than we were previously aware of. Here, Dr. Trujillo discusses how to use ketamine safely in clinical practice.

Expert Q&A

Psychedelics and Addiction

April 1, 2024

Snehal Bhatt, MD

Snehal Bhatt, MD.

Chief, Addiction Psychiatry; Professor, Psychiatry and Behavioral Sciences, University of New Mexico, Albuquerque, NM.

Dr. Bhatt has no financial relationships with companies related to this material.

Dr. Bhatt outlines the latest developments in therapeutic uses of psychedelic medications. He highlights the great opportunities as well as the potential drawbacks. He details some of his own work in the use of psilocybin for the treatment of alcohol use disorder and advises clinicians how to discuss psychedelics with their patients.

Research Update

Can Psilocybin Treat Alcohol Use Disorder?

October 31, 2023

Aniruddha Deka, MD

Aniruddha Deka, MD. Dr. Deka has no financial relationships with companies related to this material.

Recent preliminary research reveals that psilocybin helped participants with alcohol use disorder cut back on drinking. Dive in to discover how this psychedelic compound might offer hope for patients who have found other current treatments ineffective.

CARLAT WEBINAR

Psychedelics In Psychiatric Practice

September 12, 2023

Garrett Rossi, MD.

0.50 CME Credits. Despite limitations in current depression and PTSD treatments, there is a renewed interest in the therapeutic potential of these medications, which we'll explore in this webinar.

Expert Q&A

Psychedelic-Assisted Psychotherapy

June 1, 2023

Jeffrey Guss, MD

Jeffrey Guss, MD.

Psychiatrist and psychoanalyst. Clinical Assistant Professor of Psychiatry at NYU Grossman School of Medicine. Faculty at the NYU Postdoctoral Program in Psychotherapy and Psychoanalysis.

Dr. Guss has no financial relationships with companies related to this material.

What actually happens during psychedelic psychotherapy? Dr. Guss walks us through the steps.
1) preparation, 2) dosing, and 3) integration, where the insights gained from psychedelic experiences are turned into action in the real world.

Clinical Update

A Psychedelic Primer

June 1, 2023

Chris Aiken, MD and Garrett Rossi, MD.

Chris Aiken, MD. Editor-in-Chief of The Carlat Psychiatry Report. Assistant Professor, NYU Langone Department of Psychiatry. Practicing psychiatrist, Winston-Salem, NC.

Garrett Rossi, MD. Inpatient/Consult Attending Psychiatrist, AtlantiCare Regional Medical Center, Pomona, NJ.

The authors have no financial relationships with companies related to this material.

How did a dangerous drug of abuse become a therapeutic panacea?

MDMA-Assisted Therapy for Severe PTSD

January 31, 2022

Michael Posternak, MD.

Michael Posternak, MD. Dr. Posternak has disclosed no relevant financial or other interests in any commercial companies pertaining to this educational activity.

MDMA is being repurposed as part of drug-assisted psychotherapy for PTSD, and this trial will help determine whether it gains FDA approval for that use.